Pfizer (New York) is voluntarily recalling metronidazole, ciprofloxacin, and ondansetron intravenous products because of the presence of floating matter and non-sterility discovered by the manufacturer Claris Lifesciences.
Pfizer (New York) is voluntarily recalling metronidazole, ciprofloxacin, and ondansetron intravenous (i.v.) products because of the presence of floating matter and non-sterility discovered by the manufacturer Claris Lifesciences (Ahmedabad, Gujarat, India). Pfizer made the announcement on June 3, following a recall initiated by Claris for all lots of the i.v. products metronidazole, ciprofloxacin, and ondansetron. These products were all manufactured on the same manufacturing line and sold under the Claris, Sagent Pharmaceuticals (Schaumburg, IL), Pfizer, and West-Ward Pharmaceuticals (Eatontown, NJ) labels.
Pfizer began distributing these Claris products to hospitals, wholesalers, and distributors in the US market this year under a licensing agreement with Claris. In 2009, Pfizer formed the agreement with Claris for the rights to 15 generic injectable drugs.
Pfizer is halting distribution of all sterile injectable products in i.v. bags licensed from Claris Lifesciences and is voluntarily recalling the products already distributed. Pfizer has distributed these products only in the US, according to Pfizer. The recall is being conducted with the knowledge of FDA. Of approximately 1.7 million i.v. bags licensed for distribution from Claris, approximately 1.3 million, or about 80%, currently remain in Pfizer’s control, according to Pfizer. Pfizer said it has received no customer reports of quality issues related to the i.v. bagged medicines from Claris Lifesciences.
All lots of the following products are affected by this recall:
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.